Impaired health status in Type D patients following PCI in the drug-eluting stent era
International Journal of Cardiology , Volume 114 - Issue 3 p. 358- 365
Background: Drug-eluting stenting reduces restenosis post-percutaneous coronary intervention (PCI), but subgroups of patients may not benefit optimally from this procedure. We examined the impact of Type D personality on health status over time and the clinical relevance of Type D as a predictor of impaired health status at 12 months in unselected post-PCI patients. Methods: Consecutive patients (n = 692) participating in the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Type D Scale at 6 months and the Short Form Health Survey 36 (SF-36) at 6 and 12 months post-PCI. Results: Although there was a significant improvement in health status over time (p < 0.001), Type D patients reported a substantially lower score on all health status domains of the SF-36 compared with non-Type D patients (p < 0.001). Type D personality was an independent predictor of impaired health status on all SF-36 sub domains at 12 months except for physical functioning, adjusting for baseline demographic and clinical variables and health status at 6 months. In these adjusted analyses, Type D personality increased the likelihood of impaired health status at 12 months post-PCI from 60% (OR: 1.60; 95% CI: 1.04-2.46) to almost 300% (OR: 3.99; 95% CI: 2.52-6.32), varying among the parameters analyzed. Conclusions: Type D personality was associated with impaired health status in post-PCI patients treated in the drug-eluting stent era. The role of personality factors as determinants of clinical outcome and health status should not be overlooked as these factors may have much explanatory power.
|, , , ,|
|International Journal of Cardiology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Pedersen, S.S, Denollet, J, Ong, A.T.L, Serruys, P.W.J.C, Erdman, R.A.M, & van Domburg, R.T. (2007). Impaired health status in Type D patients following PCI in the drug-eluting stent era. International Journal of Cardiology, 114(3), 358–365. doi:10.1016/j.ijcard.2005.12.018